0001181431-15-008322.txt : 20150615 0001181431-15-008322.hdr.sgml : 20150615 20150615170029 ACCESSION NUMBER: 0001181431-15-008322 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150612 FILED AS OF DATE: 20150615 DATE AS OF CHANGE: 20150615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Avalanche Biotechnologies, Inc. CENTRAL INDEX KEY: 0001501756 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 205258327 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1035 O?BRIEN DRIVE, SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-272-6269 MAIL ADDRESS: STREET 1: 1035 O?BRIEN DRIVE, SUITE A CITY: MENLO PARK STATE: CA ZIP: 94025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bain Linda CENTRAL INDEX KEY: 0001578407 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36579 FILM NUMBER: 15931787 MAIL ADDRESS: STREET 1: C/O BLUEBIRD BIO, INC. STREET 2: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 rrd425765.xml X0306 4 2015-06-12 0 0001501756 Avalanche Biotechnologies, Inc. [AAVL] 0001578407 Bain Linda C/O AVALANCHE BIOTECHNOLOGIES, INC. 1035 O'BRIEN DRIVE, SUITE A MENLO PARK CA 94025 0 1 0 0 Chief Financial Officer Common Stock 2015-06-12 4 M 0 3500 3.15 A 12500 D Common Stock 2015-06-12 4 S 0 3500 39.9414 D 9000 D Stock Option (Right to Buy) 3.15 2015-06-12 4 M 0 3500 0.00 D 2024-04-21 Common Stock 3500 233000 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. This transaction was executed in multiple trades in prices ranging from $39.8100 to $40.1900, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Twenty-five percent (25%) of the shares subject to the option vested and became exercisable on the first anniversary measured from April 14, 2014, and the remaining shares subject to the option vest in 36 successive, equal installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. /s/ Michael Swartzburg, Attorney-in-Fact for Linda Bain 2015-06-15